

ISSN-0973-9122 (Print) • ISSN-0973-9130 (Electronic)

Volume 15

Number 4

October-December 2021



# Indian Journal of Forensic Medicine & Toxicology

Website: [www.ijfmt.com](http://www.ijfmt.com)

Official Organ of Indian Association of Medico-Legal Experts (Regd.)

# Indian Journal of Forensic Medicine & Toxicology

## EDITOR in Chief

**Prof. R K Sharma**

Formerly at All India Institute of Medical Sciences, New Delhi, E-mail: editor.ijfmt@gmail.com

## EDITOR

**Prof. Dr. Adarsh Kumar**

Forensic Medicine & Toxicology, AIIMS, New Delhi

### INTERNATIONAL EDITORIAL ADVISORY BOARD

1. **Prof Mete Gulmen** Cukurova University, TURKEY
2. **Prof. Leandro Duarte De Carvalho**, Minas Gerais, Belo Horizonte, Brazil
3. **Prof. Donata Favretto** (Full Professor) Forensic Toxicology at University of Padova, Italy
4. **Prof. Babak Mostafazadeh** Department of Forensic Medicine & Toxicology, Shahid Beheshti University of Medical Sciences, Tehran-Iran
5. **Prof Halis Dokgoz**, Mersin University, TURKEY
6. **Prof Jozef Sidlo**, Comenius University, Bratislava, SLOVAKIA
7. **Dr. Rahul Pathak** (Lecturer) Forensic Science, Dept of Life Sciences Anglia Ruskin University, Cambridge, United Kingdom
8. **Dr. Hareesh** (Professor & Head) Forensic Medicine, Ayder Referral Hospital, College of Health Sciences, Mekelle University, Mekelle Ethiopia East Africa
9. **Dr. Mokhtar Ahmed Alhrani** (Specialist) Forensic Medicine & Clinical Toxicology, Director of Forensic Medicine Unit, Attorney General's Office, Sana'a, Yemen
10. **Dr. Sarathchandra** Kodikara (Senior Lecturer) Forensic Medicine, Department of Forensic Medicine, Faculty of Medicine, University of Peradeniya, Sri Lanka
11. **Dr Noha A. Magdie El Rafie**, Forensic Toxicology, Ain Shams University, Cairo, EGYPT

### SCIENTIFIC COMMITTEE

1. **Prof Udai Pratap Singh**, Department of Anthropology Lucknow University Lucknow
2. **Dr Anil Rahule** (Associate Professor) Dept of Anatomy, Govt Medical College Nagpur
3. **Dr Shankar Bakkanwar** (Associate Professor) Forensic Medicine, Kasturba Medical College, Manipal, Karnatakad
4. **Dr K. Ravikumar** Raksha Shakti University, Ahmedabad, Gujrat.
5. **Dr. Pragnessh Parmar** (Associate Professor) Forensic Medicine, Valsad, Gujrat
6. **Dr Vandana Mudda** (Awati) (Associate Prof) Dept of FMT, M.R. Medical College, Gulbarga, Karnataka,
7. **Dr. Asha Srivastava** (Senior Scientific Officer) Forensic Psychology, Central Forensic Science Laboratory, CBI, Delhi
8. **Dr. Lav Kesharwani** (Asst.Prof.) School of Forensic Science, Sam Higginbottom Institute of Agriculture Technology & Sciences, Allahabad U.P,
9. **Dr. Anu Sharma** (Associate Prof) Dept of Anatomy, DMCH, Ludhiana (PB)
10. **Dr. Shalini Gupta** ( Prof ) Oral Pathology and Microbiology, Dental Sciences King George Medical University, Lucknow, UP
11. **Dr Rituja Sharma**, Associate Prof, Law Banasthali Vidyapeeth Jaipur

"Indian Journal of Forensic Medicine & Toxicology" is peer reviewed quarterly journal. It deals with Forensic Medicine, Forensic Science, Toxicology, DNA fingerprinting, sexual medicine and environment medicine. It has been assigned International standard serial No. p-0973-9122 and e- 0973-9130. The Journal has been assigned RNI No. DELENG/2008/21789. The journal is indexed with Index Copernicus (Poland) and is covered by EMBASE (Excerpta Medica Database). The journal is also abstracted in Chemical Abstracts (CAS) database (USA). The journal is also covered by EBSCO (USA) database. The Journal is now part of UGC, DST and CSIR Consortia. It is now official publication of Indian Association of Medico-Legal Experts (Regd.).

### NATIONAL EDITORIAL ADVISORY BOARD

#### Chairman

**Prof Sudhir K Gupta** - Head, Department of Forensic Medicine  
All India Institute of Medical Sciences, New Delhi

#### Members

1. **Prof. SK Dhatarwal**, Forensic Medicine, PGIMS, Rohtak, Haryana
2. **Prof. N K Aggrawal** Forensic Medicine, UCMS, Delhi
3. **Prof Ajay Ghangale** Forensic Medicine Dr DY Patil Medical College, Pune, Maharashtra
4. **Dr. Amar Jyoti** Patwory Professor, Forensic Medicine NEIGRIHMS, Shillong
5. **Dr S. Venkata Raghava** Professor, Forensic Medicine, Bangalore Medical College, Bengaluru
6. **Prof Praveen Arora**, Professor Department of Forensic Medicine & Toxicology, SAIMS, Indore
7. **Dr. Pankaj Datta** (Principal & Head) Department of Prosthodontics, Indraprastha Dental College & Hospital, Ghaziabad
8. **Dr. Mahindra Nagar** (Head) Department of Anatomy, UCMS & GTB Hospital, Delhi
9. **Dr. Virender Kumar Chhoker** Professor Forensic Medicine and Toxicology, Santosh Medical College, Ghaziabad, UP
10. **Dr. Dayanand G Gannur** (Professor) Department of Forensic Medicine & Toxicology, Shri BM Patil Medical College, Hospital & Research centre, Bijapur, Karnataka
11. **Dr. Alok Kumar** Professor Department of Forensic Medicine & Toxicology, UP Rural Institute of Medical Sciences and Research, Saifai, Etawah, U.P.

Print-ISSN:0973-9122 Electronic - ISSN: 0973-9130

Frequency: Quarterly, © All Rights reserved The views and opinions expressed are of the authors and not of the Indian Journal of Forensic Medicine & Toxicology. Indian Journal of Forensic Medicine & Toxicology does not guarantee directly or indirectly the quality or efficacy of any products or service featured in the advertisement in the journal, which are purely commercial.

Website: [www.ijfmt.com](http://www.ijfmt.com)

#### Editor

**Dr. R.K. Sharma**  
Institute of Medico-legal Publications  
Logix Office Tower, Unit No. 1704, Logix City Centre Mall, Sector- 32, Noida  
- 201 301 (Uttar Pradesh)

#### Printed, published and owned by

**Dr. R.K. Sharma**  
Institute of Medico-legal Publications  
Logix Office Tower, Unit No. 1704, Logix City Centre Mall, Sector- 32, Noida  
- 201 301 (Uttar Pradesh)

#### Published at

**Institute of Medico-legal Publications**  
Logix Office Tower, Unit No. 1704, Logix City Centre Mall, Sector- 32, Noida  
- 201 301 (Uttar Pradesh)

## XII

149. Correlation between Gestational Weight Gain in the Second and Third Trimester and Preeclampsia Risk: A Study From Indonesia..... 1072  
*Ernawati Ernawati, Lilis Kurniawati, Sri Umijati*
150. The Impact of Extra-Weighted Exercises in Improving Physical Abilities Towards Accurate Ace Shots in Volleyball Game ..... 1079  
*Ethar Hamdi Abdulrahman, Adnan Fad'us Omar*
151. Correlation of HIF-1 $\alpha$ , CXCR4 and MMP13 Expression in Laryngeal Squamous Cell Carcinoma with Cervical Nodal Status..... 1086  
*Etty Hary Kusumastuti, Anny Setijo Rahaju, Alphania Rahniayuw, Sjahjenny Mustokoweni, Rovi Anggoro, Muhtarum Yusuf, I Ketut Sudiana*
152. Effectiveness of Video Assisted Teaching (VAT) on Jacobson Progressive Muscle Relaxation (JPMR) Exercises to Reduce the Stress Level among B.Sc. Nursing Students..... 1096  
*Deepak Kumar Shandily, Tapti Bhattacharjee, Ramandeep Kaur Dhillon*
153. Mandibular Foramen –The Peephole..... 1103  
*Deepali P Mohite, Prakash M Mohite, Devendra Palve, Alka H Hande*
154. A Study to Assess the Effect of Food Consumption Pattern on Health Status among Nursing Students at Dinsha Patel College of Nursing, Nadiad..... 1109  
*Dhara Vyas, Fiza Sherasiya, Ami Patel*
155. The Undernutrition Prevalence of Under-Two-Years Infant in Indonesia: Do breastfeeding Practices Ecologically Matter?..... 1113  
*Fandaruzzahra Putri Perdani, Agung Dwi Laksono, Djazuly Chalidyanto, Fandaruzzahra Putri Perdani*
156. Development of Surface Coating based Hybrid Acrylic Copolymers for Coating Application, Preparation, Characterization and Processing..... 1120  
*Farah Safi Khliwi, Mohamed Ali Mutar, Ramaah Abdulhassan Sabit; Entidhar Kadhim Sahib*
157. Evaluation of Primigravida Women's Childbirth Self-efficacy at Al-Elwea Maternity Hospital in Baghdad City..... 1127  
*Fatima Fadel Benyian, Rabea Mohsen Ali*
158. Neoplasia of the Nictitating Membrane in A Domestic Short-Haired Cat based on Cytology of Fine Needle Aspiration ..... 1134  
*Fatimah Alaydrus, Lita Rakhma Yustinasari, Juliano Mwenda Ntoruru*
159. Nursing Intervention Program for Enhancing Coping Patterns among Nursing Students..... 1137  
*Fatma Adel Ahmed Ahmed, Sorayia Ramadan Abd El-fattah, Galila Shawky El-Ganzory, Hanaa Ezz El-din Prince*
160. Molecular Docking Human Plasma Kallikrein to Prevent Acute Respiratory Distress Syndrome(ARDS) in COVID-19 Patient..... 1146  
*Feriawan Tan, Cindy ApriliaEkaPrasanty, Anna Surgean Veterini, YuaniSetiawati, Rizki Awaluddin, Fadilah Fadilah, Siti Khaerunnisa*

# Correlation of HIF-1 $\alpha$ , CXCR4 and MMP13 Expression in Laryngeal Squamous Cell Carcinoma with Cervical Nodal Status

Etty Hary Kusumastuti<sup>1,4</sup>, Anny Setijo Rahaju<sup>1,4</sup>, Alphania Rahniayu<sup>1,4</sup>, Sjahjenny Mustokoweni<sup>1,4</sup>, Rovi Anggoro<sup>1</sup>, Muhtarum Yusuf<sup>2,4</sup>, I Ketut Sudiana<sup>3</sup>

<sup>1</sup>Researcher, Department of Anatomical Pathology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia, <sup>2</sup>Associate Professor, Department of Otolaryngology-Head and Neck Surgery, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia, <sup>3</sup>Professor, Department of Anatomical Pathology, Faculty of Medicine Universitas Airlangga, Surabaya, Indonesia, <sup>4</sup>Dr. Soetomo General Academic Hospital, Surabaya, Indonesia

## Abstract

**Background:** Laryngeal carcinoma is the most common malignancy of the upper respiratory tract, more than 98% are squamous cell carcinoma (SCC). New method is necessary for identifying and predicting nodal metastasis in laryngeal SCC. Overproliferating tumor cells will induce hypoxia and release HIF-1 $\alpha$ , which in turn will upregulate CXCR4. CXCR4 then will induce MMP13, a protein that degrade extracellular matrix (ECM), thus promoting metastatic process.

**Methods:** A cross sectional study, using 30 samples of laryngeal SCC, divided into two groups: based on cervical lymph node status. All samples were stained immunohistochemically against HIF-1 $\alpha$ , CXCR4 and MMP13 antibody. The expressions were evaluated using immunoreactive score (IRS).

**Result:** There were significant difference among HIF1 $\alpha$ , CXCR4, and MMP13 in laryngeal SCC with positive nodal metastasis group compared to negative nodal metastasis group ( $p < 0,05$ ). There was no significant correlation between HIF-1 $\alpha$  expression and CXCR4 expression ( $p = 0,403$ ) ( $p > 0,05$ ). There were significant correlation between HIF-1 $\alpha$  and MMP13 expression ( $r_s = 0,499$ ), and between CXCR4 and MMP13 expression ( $r_s = 0,409$ ). **Conclusion:** There were significant differences in HIF-1 $\alpha$ , CXCR4 and MMP13 immunoexpression in laryngeal SCC with cervical nodal metastasis compared to laryngeal SCC without cervical nodal metastasis. There was a positive correlation between HIF-1 $\alpha$  and MMP13 expression, positive correlation between CXCR4 and MMP13 expression, but there was no correlation between HIF-1 $\alpha$  and CXCR4 expression.

**Keywords:** Laryngeal carcinoma, lymph node metastasis, HIF-1 $\alpha$ , CXCR4, MMP13

## Background

Laryngeal carcinoma is the most common malignancy of the upper respiratory tract. Globocan estimates that there will be 177,422 new cases and 94,771 deaths due to laryngeal carcinoma worldwide in 2018.<sup>1</sup> More than 98% of laryngeal malignancies are well differentiated SCC.<sup>2</sup>

Prognosis of laryngeal carcinoma depends greatly by tumor stadium. Laryngeal carcinoma confined to

glottis has good 5 years survival rate (YSR), up to 85-95%, while presence of nodal metastasis will reduce 5 YSR significantly to 50%. The important significant single prognostic indicator of laryngeal carcinoma is the cervical nodal status.<sup>3,4</sup>

Identification of nodal metastasis in laryngeal carcinoma patients is not always easy. Probability of nodal metastasis without palpable nodal enlargement is about 13,7-37%, and better identification methods is indispensable.<sup>5</sup>

In SCC there will be changes in microenvironment of the tumor caused by proliferation of tumor cells. Up to certain tumor volume, blood and nutrients supply become inadequate and lead to tissue hypoxia. Hypoxia will induce HIF-1 $\alpha$ , which is a major regulator of cellular response to changes in oxygen concentration supporting the adaptation of tumor cells to hypoxia in an oxygen-deficient tumor microenvironment.<sup>6</sup> Overexpression of HIF-1 $\alpha$  which in turn upregulates CXCR4.<sup>7</sup>

Chemokine is a family of chemotactic that modulate cell movement and positioning, and act by coupling to G-protein coupled receptor. CXCR4 is a unique chemokine receptor because it has exclusive interaction with its ligand, CXCL12. The binding of CXCR4 and CXCL12 will initiates various downstream signaling pathways, resulting in various responses such as rising intracellular calcium, genetic transcription, cell proliferation, migration, adhesion, and invasion. CXCR4 is a critical tumor marker with a proven role in cancer progressivity and metastasis, but its role in laryngeal cancer is not yet well studied.<sup>8,9</sup>

Infiltration of cancerous cell to the surrounding tissue is an important behavior in cancer progressivity. Proteolytic enzymes such as matrix metalloproteases (MMPs) contribute to tumor expansion by degrading extracellular matrix (ECM) components. Some studies showed expression of MMP in SCC. MMP13 has a vital role in MMP activation, and it's also expressed in some head and neck SCC.<sup>10,11</sup> Meanwhile, its role in nodal metastasis is not yet well known.

This study aims to analyse the expression of HIF-1 $\alpha$ , CXCR4, and MMP13 in laryngeal SCC to unveil the roles of those markers in nodal metastasis process, which is expected to be an invaluable prognostic biomarker.

## Material and Methods

This is an observational analytic study with cross-sectional approach. The population consists of all laryngeal SCC tissues with and without cervical nodal metastasis in paraffin blocks, archived in Anatomical Pathology Laboratory of Dr. Soetomo General Academic

Hospital in Surabaya, during 2013 – 2016 period. The samples are 30 laryngeal SCC tissues in paraffin blocks from laryngectomy specimens, taken by random sampling methods.

In this study, immunoexpressions of these three proteins were evaluated by immunohistochemistry examination. We used monoclonal antibody against HIF-1 $\alpha$  (NB100-131, Novusbio) with 1:100 dilution, monoclonal antibody against CXCR4 (sc-53534, Santa Cruz Biotechnology, Inc., Texas, USA) with 1:50 dilution, and monoclonal antibody against MMP13 (sc-101564, Santa Cruz Biotechnology, Inc., Texas, USA) with 1:50 dilution. All antigen retrievals were done using decloaking chamber (heat-induced epitope retrieval) with DIVA solution in 110°C for 30 minutes.

HIF-1 $\alpha$  was positive if expressed in nucleus or cytoplasm of tumor cells. CXCR4 was positive if expressed in the nucleus, cell membrane or cytoplasm. MMP13 was positive if expressed in cytoplasm of tumor cells.

HIF-1 $\alpha$ , CXCR4, and MMP13 immunohistochemical staining were assessed using semiquantitative Immunoreactivity Score (IRS) refferancing to Remmele and Stegner. To determine the IRS, the percentage of positive tumor cells was classified into five grade (no positive cells = 0, <10% of positive cells = 1, 10-50% positive cells = 2, 51-80% positive cells = 3, and > 80% positive cells = 4). Then the grade of positive cells percentage is multiplied by the grade of staining intensity which is divided into 4 grades (no staining = 0, weak staining = 1, moderate staining = 2, and strong staining = 3). The final IRS score ranges from 0-12.<sup>12</sup> The assessment was performed by two pathologists.

All datas were analyzed statistically using SPSS program. Analysis of expression differences of HIF-1 $\alpha$ , CXCR4, and MMP13 was done with Mann-Whitney test. Analysis of correlation was done with Spearman correlation test. Statistical result is significant if  $p < 0,05$ .

## Result

Mean age of all 30 patients was 55,9 $\pm$ 8,36 years

old. The youngest was 49 years old and the oldest was 75. Patients were grouped into 4 groups with 10 years interval. As many as 53,33% patients were in the 51-60 years old group. Most patients were male. Out of 30 cases, there were only 2 female patients.

As many as 80% or 24 out of 30 cases of laryngeal SCC in this study were well differentiated. Four cases (12,33%) were moderately differentiated, and only 2 cases (6,67%) were poorly differentiated. Only 1 case (3,33%) was diagnosed in early stage (T1). Most cases, 43,33% or 13 cases of these cases were resected in stadium T3. There were 15 cases with cervical nodal metastasis; 8 cases (26,67%) in stadium N1 (metastasis to one ipsilateral lymph node with diameter  $\leq 3$  cm), and

7 cases with stadium N2.

Statistical analysis with Mann-Whitney showed that there was a significant difference among median scores of HIF1 $\alpha$ , CXCR4 and MMP13 expression in laryngeal SCC without nodal metastasis group compared to laryngeal SCC with nodal metastasis group ( $p < 0,05$ ), as depicted in table 5.2.

In this study, Spearman correlation test showed no significant correlation between HIF-1 $\alpha$  and CXCR4 expression, with  $p = 0,403$  ( $p > 0,05$ ). Meanwhile, the test showed positive correlation between HIF-1 $\alpha$  and MMP13, and between CXCR4 and MMP13 with  $r_s = 0,499$  and  $r_s = 0,409$  ( $p < 0,05$ ), respectively.

**Table 1: Sample Characteristics (n=30)**


Parameter	Frequency	Percentage (%)
Age	£50	26,67
	51-60	53,33
	61-70	6,67
	>70	13,33
Sex	Male	93,33
	Female	6,67
Tumor Differentiation	Well	80
	Moderate	13,33
	Poor	6,67
Stadium T	1	3,33
	2	30
	3	43,33
	4a	23,33
	4b	0
Stadium N	0	50
	1	26,67
	2a	3,33
	2b	13,33
	2c	6,67
	3	0

**Table 2: HIF1 $\alpha$ , CXCR4 and MMP13 Expression in Laryngeal SCC with and without Nodal Metastasis**


Stadium	n	HIF1a Expression					Mann Whitney P
		$\bar{x}$	SD	Median	Min	Max	
Without nodal metastasis	15	1	1,41	0	0	4	0,000*
With nodal metastasis	15	4,47	2,03	4	2	9	

Stadium	n	CXCR4 Expression					Mann Whitney P
		$\bar{x}$	SD	Median	Min	Max	
Without nodal metastasis	15	6,6	3,11	6	3	12	0,023*
With nodal metastasis	15	9,4	2,99	9	4	12	


Stadium	n	MMP13 Expression					Mann Whitney P
		$\bar{x}$	SD	Median	Min	Max	
Without nodal metastasis	15	1	0,85	1	0	3	0,000*
With nodal metastasis	15	2,8	1,26	2	0	4	



**Figure 1. HIF1 $\alpha$  expression, stained positively in cytoplasm of tumor cells. A, with weak intensity. Internal positive control was inflammatory cells (arrow) (HE, 200x). B, with strong intensity (HE, 200x).**



**Figure 2. CXCR4 expression, stained positively in cytoplasm and nucleus of tumor cells. A, with weak intensity (HE, 200x). B, with strong intensity (HE, 200x).**



**Figure 3. MMP13 expression, stained positively in cytoplasm of tumor cells. A, with weak intensity (HE, 200x). B, with moderate intensity (HE, 200x).**

### Discussion

In this study, statistical analysis showed that there was a significant difference in HIF-1 $\alpha$  expression in laryngeal SCC with nodal metastasis compared to laryngeal SCC without nodal metastasis ( $p < 0.05$ ). HIF-1 $\alpha$  was expressed stronger in metastasis group. This finding is in concordance with previous studies, such as studies by Wu et al and Popov et al who studied HIF-1 $\alpha$  expression in laryngeal SCC.<sup>13,14</sup> and also in oral SCC.<sup>15</sup> Zhou et al in a meta-analysis study showed that HIF-1 $\alpha$  associated with not only lymph node metastasis, but also tumor size, tumor stage and overall survival.<sup>16</sup>

HIF-1 is an important factor regulating cell adaptation to oxygen deprivation. In a normoxic condition, the proline and lysine residues of HIF-1 $\alpha$  subunits are hydroxylated by oxygen-dependent prolyl-4-hydroxylases (PHDs). Von Hippel-Lindau E3 ubiquitin ligase binds to hydroxylated HIF-1 $\alpha$  and acts as a substrate recognition component of E3 ubiquitin ligase complex, which leads to proteasomal degradation of HIF protein. In solid tumors like laryngeal SCC, hypoxia is commonly found since there is a higher proliferation rate and intratumoral oxygen will be rapidly depleted. In hypoxic condition, the activity of PHDs and FIHs are suppressed, and HIF-1 $\alpha$  translocates to the nucleus to bind with HIF-1 $\beta$ . The heterodimeric HIF-1 $\alpha$  with HIF-



1 $\beta$  with the help of coactivators such as cyclic adenosine monophosphate response element-binding protein (CBP) and acetyltransferase (p300), then bind to the target gene hypoxia response element (HRE), resulting in their transcriptional upregulation. HIF-1 $\alpha$  will then induce various pathways which influence survival, proliferation, apoptosis, intratumoral angiogenesis, and many other processes.<sup>6,17</sup>

Statistical analysis showed that there were significant differences of in CXCR4 expression in laryngeal SCC with nodal metastasis compared to laryngeal SCC without nodal metastasis ( $p < 0,05$ ). Previous studies on laryngeal and head and neck SCC were also found similar results.<sup>18-20</sup> A study by Toyoma et al even proved that inactivation of CXCR4 will inhibit invasion and migration of tumor cells in SCC hypopharynx.<sup>21</sup>

Overexpression of CXCR4 is found in many malignancies. This is caused by CXCR4 upregulation by HIF-1 $\alpha$  and HIF-2 secreted by malignant cells as a response to their increased oxygen demand.<sup>7</sup> CXCR4 upregulation can also be caused by DNA demethylation of CXCR4 promotor, a particular process detected in various types of cancer.<sup>22</sup> CXCR4-CXCL12 binding can increase MMP2 expression and inhibit tissue inhibitors of MMP. In addition, CXCL12 can promote the separation of tumor cells from tumor tissue and activated several cell adhesion molecules, and induce them to secrete more MMP and VEGF to dissolve ECM. These mechanisms contribute to tumor growth, angiogenesis, and metastasis.<sup>23</sup> Biasci et al, proved that inhibition of CXCR4 combined with blockade of PD-1/PD-L1 T cell check points can induce T lymphocyte infiltration, resulting in an anti-cancer response.<sup>24</sup> A study conducted by Tulotta et al showed that CXCR signaling supports the interaction between tumor cells and host neutrophils in developing tumor metastasis.<sup>25</sup>

This study also showed a significant difference in MMP13 expression in laryngeal SCC with nodal metastasis compared to laryngeal SCC without nodal metastasis ( $p < 0,05$ ). In this study, the median MMP13 expressions were stronger in laryngeal SCC with nodal

metastasis group. Previous studies in laryngeal SCC.<sup>26,27</sup> The study conducted by Huang showed that siMMP13 knockdown not only reduced the tumor invasion and migration, but also decreased the adhesion abilities of oral cancer cells. It is supported that MMP13 promotes invasion and metastasis in oral cancer cells.<sup>28</sup>

MMP13 has a wide range proteolytic capacity. It is produced and secreted from many cell types as a precursor form (pro MMP13), which can be activated by plasmin, MMP2, MMP3, and MMP14. MMP13 or collagenase-3 has the ability to degrade not only fibrillary collagen (type I, II, III, V, and XI), but also basal membrane, cartilage, collagen type IV, IX, X and XIX, gelatin, fibrillin-1, tenascin, aggrecan, perlecan fibronectin, and osteonectin. MMP13 is expressed physiologically in conditions where rapid and effective remodelling of ECM are necessary, such as in fetal bone development and adult bone remodelling, and gingival and foetal skin wound healing. MMP13 is expressed pathologically in conditions involving overdegradation of ECM such as in rheumatoid arthritis, atherosclerosis, osteoarthritis and malignancy.<sup>29-31</sup>

In laryngeal SCC, tumor cells proliferate overwhelmingly. Tumor cells will secrete proteolytic enzymes and induce stromal cells, fibroblasts and inflammatory cells, in particular tumor associated macrophage (TAM), to produce MMP. MMP13 is a central key for other MMP cascade activation like MMP2, MMP3 and MMP9. All MMPs will then degrade ECM and basal membrane components together, facilitating tumor cells to invade stromal tissue and metastasize to lymph nodes and distant organs.<sup>32,33</sup>

Spearman correlation test showed no significant correlation between HIF-1 $\alpha$  and CXCR4 expression,  $p = 0,403$  ( $p > 0,05$ ). This finding is inconsistent with previous studies that showed a positive correlation between HIF-1 $\alpha$  and CXCR4 expression in many types of malignancy, and also in laryngeal SCC.<sup>14,34</sup>

HIF-1 $\alpha$  expression of laryngeal SCC tumor cells in this study tends to be low, while CXCR4 tends to be overexpressed. HIF-1 $\alpha$  is known to be a major regulator

for CXCR4 upregulation, hence a low expression of HIF-1 $\alpha$  should be followed by low expression of CXCR4. This contradictory finding could be caused by other molecular mechanisms which can also alter both protein levels, since molecules and biomarkers interactions in carcinogenesis are very complex and dynamic processes. As mentioned before, CXCR4 is not regulated solely by HIF-1 $\alpha$ . Many malignancies had DNA demethylation of CXCR4 promotor, this will also upregulate CXCR4. Changes in multiple growth factors and transcription factors were also upregulate of CXCR4.<sup>22,35</sup> A recent study from Izumi et al also found that CXCR4 could be secreted by stromal myofibroblasts, known as cancer-associated fibroblasts (CAFs).<sup>36</sup>

In this study, Spearman correlation test showed positive correlation between HIF-1 $\alpha$  and MMP13 expression in laryngeal SCC,  $r_s = 0,499$  ( $p < 0,05$ ). The stronger HIF-1 $\alpha$  expression, the stronger MMP13 expression.

Hypoxia condition with high HIF-1 $\alpha$  level will influence many mechanisms for tumor cells survival. HIF-1 $\alpha$  regulates some proteins such as protein Twist, MMP-2, MMP-9, VEGF, and CXCR4/SDF-1. Matrix metalloproteinase like MMP-2, MMP-9 and MMP13 will degrade ECM surrounding tumor cells, eventually facilitate invasion of tumor cells through basal membrane into lymph and blood vessels to metastasize to lymph node and distant organs.<sup>37</sup>

In this study, Spearman correlation test also found positive correlation between CXCR4 and MMP13 expression,  $r_s = 0,409$  ( $p < 0,05$ ). The stronger CXCR4 expression, the stronger MMP13 expression. Previous studies also found similar results, not only in laryngeal SCC (Tan et al., 2008), but also in other malignancies such as basal cell carcinoma and colorectal cancer.<sup>38,39</sup>

CXCR4 activation will induce various downstream signaling pathways, induce EMT (epithelial to mesenchymal transition), and promote metastasis. Activated CXCR4 will dissociate to  $\alpha$  and  $\beta$  subunit.  $\beta$  subunit will activate phospholipase C- $\beta$  (PLC- $\beta$ ) and PI3K. PLC- $\beta$  will then divide phosphatidylinositol

into IP3 (inositol (1,4,5) triphosphate and diacylglycerol (DAG). IP3 will induce intracellular calcium release and then together with DAG will activate protein kinase C and MAPK/ERK pathway.<sup>40</sup> MAPK/ERK then will relay the signal to induce MMP activity for ECM degradation by promoting transcription and translation of proMMP13 to MMP13.<sup>22</sup>

Regulation of MMP13 expression by CXCR4 has been proven by Bu et al. They analyzed silencing effect of CXCR4 gene in some signaling pathways, and found a significant decrease in ERK phosphorylation level, mRNA and MMP13 protein level. This proved that CXCR4 could regulate MMP13 transcription level through ERK/NF $\kappa$ B pathway.<sup>39</sup>

## Conclusion

There were significant differences among HIF-1 $\alpha$ , CXCR4, and MMP13 expression in laryngeal SCC with nodal metastasis compared to laryngeal SCC without nodal metastasis. All three were expressed stronger in laryngeal SCC with nodal metastasis group. There was a positive correlation between HIF-1 $\alpha$  and MMP13 expression, positive correlation between CXCR4 and MMP13 expression, but there was no correlation between HIF-1 $\alpha$  and CXCR4 expression.

**Conflict of Interest:** The authors declare that they have no competing interest

**Ethical Clearance:** This study had been approved by RSUD Dr. Soetomo, Surabaya, Indonesia No. 474/Panke.KKE/VIII/2017

**Source of Funding:** Independent

**Acknowledgements:** The authors are thankful to The Anatomical Pathology Laboratory of Dr. Soetomo General Academic Hospital in Surabaya for providing the necessary facilities for this experiment.

## References

1. Bray F., Ferlay J., Sorjomataram I., Siegel R. L., Torre L. A., and Jemal A. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancer in 185 countries. *CA: A*


- cancer Journal for Clinicians*.2018;68:394-424.
2. Nocini R., Molteni G., Mattiuzzi C., Lippi G. Updates on larynx cancer epidemiology. *Chinese Journal of Cancer Research*;2020; 32 (1): 18-25.
  3. Markou K., Christoforidou A., Karasmanis I., Tsiropoulos G., Triatidis S., Constantinidis I., Vital V., and Nikolaou A. Laryngeal cancer: Epidemiological data from northern Greece and review of literature. *Hippokratia*;2013: 17 (4); pp313-318.
  4. Bradford C. R., Ferlito A., Devaney K. O., Makitie A. A., Rinaldo A. Prognostic factors in laryngeal squamous cell carcinoma. *Laryngoscope Investigative Otolaryngology*.2020.1-8.
  5. Paksoy M., Hardal U., and Caglar C. Expression of cathepsin D and E-cadherin in primary laryngeal cancers correlation with neck lymph node involvement. *Journal of Cancer Research and Clinical Oncology*, 2011;137: pp 1371-1377.
  6. Jin X., Dai L., Ma Y., Wang J and Liu Z. Implication of HIF- $\alpha$  in the tumorigenesis and progression of pancreatic cancer. *Cancer Cell International*.2020. 20: 273.
  7. Young D. A., Barter M. J., and Wilkinson D. J. 2019. Recent advances in understanding the regulation of metalloproteinases. *F1000Research*. 2019. 8 (F1000 Faculty Rev): 195; pp 1-11.
  8. Adekoya T. O., and Richardson R. M. Cytokines and chemokines as mediator of prostate cancer metastasis. *International Journal of Molecular Sciences*. 2020. 21, 4449; pp 1-29.
  9. Bao Y., Wang Z., Liu B., Lu X., Xiong Y., Shi J., Li P., Chen J., Zhang Z., Chen M., Wang L., and Wu Z. A feed-forward loop between nuclear translocation of CXCR4 and HIF- $\alpha$  promotes renal cell carcinoma metastasis. *Oncogene*. 2019. 38: pp 881-895.
  10. Hira-Miyazawa M., Nakamura H., Hirai M., Kobayashi Y., Kitahara H., Bou-Gharios G., and Kawashiri S. Regulation of programmed-death ligand in the human head and neck squamous cell carcinoma microenvironment is mediated through matrix metalloproteinase-mediated proteolytic cleavage. *International Journal of Oncology*. 2018. 52; pp 379-388.
  11. Matulka M., Konopka A., Mroczko B., Pryczynicz A., Kemon A., Groblewaka M., Sieskiewicz A., Olszewska E. Expression and concentration of Matric Metalloproteinase 9 and Tissue Inhibitor of Matrix Metalloproteinases 1 in laryngeal squamous cell carcinoma. *Disease Markers*.2019; 3136792, 9.
  12. Werner C., Dirsch O., Dahmen U., Grimm M., Schulz S., and Lupp A. Evaluation of somatostatin and CXCR4 receptor expression in a large set of prostate cancer samples using tissue microarrays and well-characterized monoclonal antibodies. *Translational Oncology*. 2020.
  13. Wu X-H., Lu Y-F., Hu X-D., Mao J-Y., Ji X-X., Yao H-T., Zhou S-H. Expression of Hypoxia-Inducible Factor-1  $\alpha$  and its significance in laryngeal carcinoma. *The Journal of International Medical Research*.2010: 38; pp 2040-2046
  14. Popov T. M., Goranova T., Stancheva G., Kaneva R., Dikov T., Chalakov I., Rangachev J., Konov D., Todorov S., Stoyanov O., Mitev V. Relative quantitative expression of hypoxia-inducible factor-1 $\alpha$ , -2 $\alpha$  and -3 $\alpha$  and vascular endothelial growth factor A in laryngeal carcinoma. *Oncology letters*,2015; 9. 2879-2885
  15. Ribeiro M., Teixeira S. R., Azevedo M. N., Fraga Jr A. C., Gontijo A. P. M., and Vencio E. F. Expression of hypoxia-induced factor-1 alpha in early-stage and in metastatic oral squamous cell carcinoma. *Tumor Biology*.2017 April 2017; pp 1-8.
  16. Zhou J., Huang S., Wang L., Yuan X., Dong Q., Zhang D., and Wang X. Clinical and prognostic significance of HIF-1 overexpression in oral squamous cell carcinoma: a meta-analysis. *World Journal of Surgical Oncology*.2017. 15: 104; pp 1-8.
  17. Lee J. W., Ko J., Ju C., and Eltzschig H. K. Hypoxia signalling in human disease and therapeutic targets. *Experimental & Molecular Medicine*.2019; 51: 68. Available on: <https://www.nature.com/articles/s12276-019-0235-1>
  18. Tan C., Chu C., Lu Y., Chang C., Lin B., Wu H.,








- Liu H., Cha S., Prakash E., Ko J., Kuo M. CXCL12/CXCR4 promotes laryngeal and hypopharyngeal squamous cell carcinoma metastasis through MMP-13-dependent invasion via the ERK1/2/AP-1 pathway. *Oxford Journal, Medical & Health & Science & Mathematics, Carcinogenesis*.2008. 29: 1519-1527.
19. Niu J., Huang Y., Zhang, L. CXCR4 silencing inhibits invasion and migration of human laryngeal cancer Hep-2 cells. *International Journal of Clinical and Experimental Pathology*;2015: 8 (6): pp 6255-6261.
  20. Al-jokhadar, Al-Mandily A., Zaid K., and Maalouf E. A. CCR7 and CXCR4 expression in primary head and neck squamous cell carcinoma and nodal metastasis - clinical and immunohistochemical study. *Asian Pacific Journal of Cancer Prevention*.2017. Vol 18; pp 1093-1104.
  21. Toyoma S., Suzuki S., Kawasaki Y., and Yamada T. SDF-1/CXCR4 induces cell invasion through CD147 in squamous cell carcinoma of the hypopharynx. *Oncology Letter*.2020: 20; pp 1817-1823.
  22. Guo F., Wang Y., Mok S. C., Xue F., Zhang W. CXCL12/ CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks; a review. *Oncogene*. 2016; pp 816-826
  23. Zhang J., Liu C., Mo X., Shi H., and Li S. Mechanisms by which CXCR4/CXCL12 cause metastatic behavior in pancreatic cancer. *Oncology Letters*.2018. 15; pp 1771-1776
  24. Biasci D., Smoragiewicz M., Conneli C. M., Wang Z., Gao Y., Thaventhiran J. E. D., Basu B., Magiera L., Jhonson T. I., Bax L., Gopinathan A., Isherwood C., Gallagher F. A., Pawula M., Hudecova I., Gale D., Rosenfeld N., Barmponakis P., Popa E. C., Brais R., Godfery E., Mir F., Richards F. M., Fearon D. T., Janowitz T., and Jodrell D. I. *PNAS*. 2020. Vol 117. No 46; pp 28960 – 28970.
  25. Tulotta C., Stefanescu C., Chen Q., Torraca V., Meijer A. H., and Snaar-Jagalska B. E. CXCR4 Signaling regulates metastatic onset by controlling neutrophil motility and response to malignant cells. *Scientific Reports*.2019. 9: 2399.
  26. Krecicki T., Fraczek M. Jelen M., Podhorska M., Szkudlarek T., Zatonski T. Expression of collagenase-1 (MMP-1), collagenase-3 (MMP-13) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in laryngeal squamous cell carcinomas. *Eur Arch Otorhinolaryngol*, 2003; 260 (9): pp 494-497.
  27. Vincent-chong V. K., Salahshourifar I., Karen-Ng L. P., Siow M. Y., Kallarakkal T. G., Ramanathan A., Yang Y., Khor G. HZ. A. A., Ismail S. M., Prepageran N. Mustafa W. M., W. Abraham M. T., Tay K. K., Cheong S. C., and Zain R. B. Overexpression of MMP13 is associated with clinical outcomes and poor prognosis in oral squamous cell carcinoma. *The Scientific World Corporation*. 2014, Article ID 897523
  28. Huang S., Law C. L., and Lyu P. Retraction: MMP13 is involved in oral cancer cell metastasis. *Oncotarget*.2016. 7 (13); pp 17144-61.
  29. Yamamoto K., Okano H., Miyagawa W., Visse R., Shitomi Y., Dudhia J., Thruberg L., Strickland D. K., Hirohata S., and Nagase H. MMP-13 is constitutively produced in human chondrocytes and co-endocytosed with ADAMTS-5 and TIMP-3 by the endocytic receptor LRP1. *Matrix Biol*.2016. 56; pp 57-73.
  30. Li H., Wang D., Yuan Y., and Min J. New insight on the MMP-13 regulatory network in pathogenesis of early osteoarthritis. *Arthritis Research & Therapy*. 2017; 19: 248: pp 1-12.
  31. Hu Q., and Ecker M. Overview of MMP13 as a promising target for the treatment osteoarthritis. *International Journal of Molecular Science*.2021. 22, 1742
  32. Yan Q., Yuan Y. Liu Y., Jingjie F., Linfang J., Yong P., Dong H., and Xiaowei Q. The Expression and Significance of CXCR5 and MMP13 in Colorectal Cancer. *Cell Biochemistry and Biophysics*.2015 [online] 01 March 2015.
  33. Kotepui M., Punsawad C., Chupeerach C., Songsri A., Charonkijkajorn L., and Petmitr S. Different expression of matrix metalloproteinase-13 in association with invasion of breast cancer.

- Contemporary Oncology*.2016. 20 (3): pp 225-228.
34. Gouveia-Fernandes S., Carvalho T., Domingues G., Bordeira-Carrico R., Dias S., and Serpa J. Colorectal cancer aggressiveness is related to fibronectin expression, driving the activation of SDF-1: CXCR axis. *International Journal of Cancer and Clinical Research*.2016: 3(8): pp 1-9.
  35. Wang Y., Xie Y., and Oupicky D. Potential of CXCR4/CXCL12 chemokine axis in cancer drug delivery. *Current Pharmacology Reports*.2016, 2: pp 1-10.
  36. Izumi D., Ishimoto T., Miyake K., Sugihara H., Eto K., Sawayama H., Yasuda T., Kiyozumi Y., Kaida T., Kurashige J., Imamura Y., Hiyoshi Y., Iwatsuki M., Iwagami S., Baba Y., Sakamoto Y., Miyamoto Y., Yoshida N., Watanabe M., Takamori H., Araki N., Tan P., and Baba H. CXCL12/CXCR4 activation by cancer-associated fibroblasts promotes integrin  $\beta 1$  clustering and invasiveness in gastric cancer. *International Journal of Cancer*.2016: 138. pp. 1207-1219.
  37. Walk E. L. and Weed S. A. Recently Identified Biomarkers That Promote Lymph Node Metastasis in Head and Neck Squamous Cell Carcinoma. *Cancers*. 2011:(3) : pp 747-772.
  38. Ciurea M. E., Cernea D., Georgescu C. C., Cotoi O. S., Patrascu V., Parvanescu H., Popa D., Parvanescu V., Ciurea R. N., and Mercur R. Expression of CXCR4, MMP13 and  $\beta$ -catenin in different histological subtype of fascial basal cell carcinoma. *Romanian Journal of Morphology and Embryology*,2013. 54 (4), pp 939-951.
  39. Ou B., Zhao J., Guan S., Feng H., Wangpu X., Zhu C., Zong Y., Ma J., Sun J., Shen X., Zheng M., and Lu A. CCR4 promotes metastasis via ERK/ NF- $\kappa\beta$ /MMP13 pathway acts downstream of TNF- $\alpha$  in colorectal cancer. *Oncotarget*.2016; Vol 7. No 30; pp 47638-47649.
  40. Zhang J., Wang X., Vikash V., Ye Q., Wu D., Liu Y., and Dong W. ROS and ROS-mediated cellular signaling. *Oxidative Medicine and Cellular Longevity*. 2016. 4350965; 18.

# Indian Journal of Forensic Medicine and Toxicology

Discontinued in Scopus as of 2020

<p><b>COUNTRY</b></p> <p>India</p> 	<p><b>SUBJECT AREA AND CATEGORY</b></p> <ul style="list-style-type: none"> <li>Environmental Science             <ul style="list-style-type: none"> <li>Health, Toxicology and Mutagenesis</li> </ul> </li> <li>Medicine             <ul style="list-style-type: none"> <li>Pathology and Forensic Medicine</li> </ul> </li> <li>Pharmacology, Toxicology and Pharmaceutics             <ul style="list-style-type: none"> <li>Toxicology</li> </ul> </li> <li>Social Sciences             <ul style="list-style-type: none"> <li>Law</li> </ul> </li> </ul>	<p><b>PUBLISHER</b></p> <p>Institute of Medico-legal Publications</p>	<p><b>H-INDEX</b></p> <p>12</p>
<p><b>PUBLICATION TYPE</b></p> <p>Journals</p>	<p><b>ISSN</b></p> <p>09739122, 09739130</p>	<p><b>COVERAGE</b></p> <p>2008-2021</p>	<p><b>INFORMATION</b></p> <p><a href="#">Homepage</a></p> <p><a href="#">How to publish in this journal</a></p> <p><a href="mailto:editor:ijfmt@gmail.com">editor:ijfmt@gmail.com</a></p>



**Indian Journal of Forensic Medicine and Toxicology**

← Show this widget in your own website

Not yet assigned quartile

SJR 2021: 0

powered by scimagojr.com

Just copy the code below and paste within your html code:

```
<a href="https://www.scimagojr.com" data-bbox="425 925 515 945">
```

**SCImago Graphica**

Explore, visually communicate and make sense of data with our **new data visualization tool**.



SURAT EXEMPTION  
(~ LETTER OF EXEMPTION ~)

Ref. No. : 0153/LOE/301.4.2/X/2020

Judul Protokol Penelitian : PERBEDAAN DAN MEKANISME RESPON BAIK DAN BURUK PADA  
KARSINOMA NASOFARING TERHADAP KEMORADIO KOMBINASI  
MELALUI ANALISIS HIF-1 $\alpha$ , CD133, SOD, HSP70, DAN APOPTOSIS

Dokumen yang disetujui : 0236/120/IX/2020 (versi: 4)

Peneliti Utama : Etty Hary Kusumastuti, dr., Sp. PA(K), FIAC

Peneliti Lain : 1. Prof. Dr I Ketut Sudhana, Des., MSi  
2. Dr Muhtarum Yusuf, dr., Sp. THT-KL (K), FICS

Instalasi/Tempat Penelitian : SMF Patologi Anatomi  
RSUD Dr. Soetomo

Komite Etik Penelitian Kesehatan RSUD Dr Soetomo menyatakan bahwa dokumen diatas sesuai dengan The Office for Human Research Protections (OHRP) dibawah persyaratan the U.S. Department of Health and Human Services (HHS) Regulasi 45 CFR bagian 46 untuk **exempt review**.



Dr. Dominicus Husada dr., SpA(K)  
Ketua Panel 4

Dr. Evelyn Komaratih dr., SpM(K)  
Sekretaris Panel 4